Patents
Literature
10 results about "Berberine Chloride" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The orally bioavailable, hydrochloride salt form of berberine, a quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation. In addition, berberine modulates lipid and glucose metabolism.
A method for improving bioavailability of puerarin
The application provides a method for improving the bioavailability of puerarin, and belongs to the field of biological preparation, wherein puerarin and berberine are prepared into a puerarin-berberine compound, preferably hydrochloric acid berberine, and the molar ratio of the puerarin-berberine compound is 1:1, the method can improve the bioavailability of puerarin by tens of times, and further significantly improves the effect of puerarin on treating metabolic diseases caused by high-fat diet, improves physiological functions from multiple aspects, and has an excellent industrial application prospect.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Berberine hydrochloride colon-targeted preparation, preparation method thereof and application of berberine hydrochloride colon-targeted preparation in treatment of type 2 diabetes mellitus
The invention discloses a berberine hydrochloride colon-targeted preparation, a preparation method thereof and application of the berberine hydrochloride colon-targeted preparation in treatment of type 2 diabetes mellitus, and belongs to the field of medicines, and berberine hydrochloride colon-targeted pellets are prepared through extrusion rolling and fluidized bed coating technologies. In-vitro test results show that the accumulative release rate of the preparation in simulated gastric juice, duodenal juice and intestinal juice within 2 hours is less than 10%; and when being transferred into simulated colon liquid (pH 7.6), the 2-hour accumulative release rate is greater than 60%, and the 4-hour accumulative release rate is greater than 80%, so that colon-targeted drug delivery can be realized, and the preparation is simple and convenient. The preparation can effectively control the blood sugar level of diabetic mice, regulate the blood fat level and improve the glucose tolerance, and more medicine choices are provided for treatment of type 2 diabetes mellitus.
Owner:SHENYANG PHARMA UNIV
Special compound preparation with analgesic and anti-inflammatory effects for periodontitis and preparation method thereof
The invention relates to the technical field of oral medicine preparations, in particular to a compound preparation special for periodontitis and having analgesic and anti-inflammatory effects and a preparation method of the compound preparation. Comprising 0.01 wt% to 0.05 wt% of capsaicin, 0.5 wt% to 1.5 wt% of propyl gallate, 0.3 wt% to 0.8 wt% of berberine hydrochloride, 2.0 wt% to 5.0 wt% of chitosan quaternary ammonium salt, 1.0 wt% to 3.0 wt% of hydroxypropyl methylcellulose K4M, 0.5 wt% to 1.2 wt% of azone, 5.0 wt% to 10.0 wt% of glycerinum, 0.5 wt% to 1.0 wt% of citric acid-sodium citrate buffer solution and the balance purified water for injection. Through combination of capsaicin (analgesic), propyl gallate (anti-inflammatory) and berberine hydrochloride (bacteriostatic), 'pain relief-inflammation control-pathogenic bacteria removal 'are synchronously carried out, an adhesion-controlled release system is formed by chitosan quaternary ammonium salt and HPMC, so that the retention time of a medicine in a periodontal pocket reaches 8-12 hours, the in-vitro release rate in 24 hours is greater than or equal to 85%, and the effect is remarkable. The local drug concentration is 4-6 times that of common gel, and frequent drug administration is avoided.
Owner:胡灿
Combined use of berberine and glabridin, preparation of self-assembled preparation and application of self-assembled preparation in colorectal cancer resistance
The invention belongs to the field of biology, and particularly relates to combined use of berberine and glabridin and application of a self-assembled preparation of the berberine and the glabridin in anti-colorectal cancer treatment. According to the application disclosed by the invention, firstly, a large amount of screening finds that the combination of berberine hydrochloride and glabridin can remarkably inhibit the proliferation of colorectal cancer cells, especially has a remarkable inhibiting effect on colorectal cancer infected by fusobacterium nucleatum, and has a synergistic effect; secondly, berberine hydrochloride and glabridin molecules form a nanoparticle preparation through a self-assembly process, the nanoparticles do not need an exogenous carrier and are uniform in particle size, the anti-colorectal cancer effect is better than that of a composition of berberine and glabridin free molecules under the same dose, the solubility and delivery efficiency of the medicine can be improved, and the bioavailability of the medicine is improved. And a new candidate strategy is provided for clinical treatment.
Owner:LANZHOU UNIV
Eutectic of puerarin and berberine hydrochloride, preparation method, composition and application thereof
The invention relates to a puerarin and berberine hydrochloride eutectic crystal and a preparation method, a composition and application thereof, in the puerarin and berberine hydrochloride eutectic crystal, the molar ratio of puerarin to berberine hydrochloride is 1: 1, the eutectic crystal has higher stability, solubility and bioavailability, and the puerarin and berberine hydrochloride eutectic crystal can be used for preparing a pharmaceutical preparation for preventing and treating diseases. The pharmaceutical composition can be used for treating inflammatory diseases, cardiovascular diseases, diabetes, bacillary dysentery, tuberculosis, scarlet fever, acute tonsillitis or respiratory tract infection.
Owner:SOUTHERN MEDICAL UNIVERSITY
A non-phospholipid lipid membrane modified yeast microcapsule carrier, its preparation method and application
ActiveCN116271083BOrganic active ingredientsPharmaceutical non-active ingredientsPharmaceutical drugDrug carrier
This invention discloses a non-phospholipid lipid membrane-modified yeast microcapsule carrier, its preparation method, and its application, belonging to the field of drug carrier technology. The invention obtains yeast microcapsules through ethanol dehydration, adsorbs and loads drugs to obtain drug-loaded yeast microcapsules, and then modifies these drug-loaded yeast microcapsules with a cationic lipid membrane to obtain yeast microcapsules modified with a non-phospholipid cationic lipid membrane coating. The non-phospholipid lipid membrane-modified yeast microcapsule carrier prepared by this invention possesses the acid stability, pH responsiveness, and ion responsiveness of cationic lipid membranes. It successfully solves the problems of poor stability, excessive drug loss in gastric juice, and low bioavailability of drugs such as berberine hydrochloride due to their ineffective retention in the intestine, thus improving the oral bioavailability of drugs such as berberine and promoting drug absorption in the intestinal environment. This provides a new approach for the research and development and use of drugs with low bioavailability in oral formulations.
Owner:DALIAN UNIV OF TECH
Use of berberine hydrochloride in combination with stachydrine for modulating gut microbiota
The application discloses a use of a pharmaceutical composition consisting of berberine hydrochloride and stachydrine in regulating intestinal flora of animals, and belongs to the technical field of medicines. The composition can selectively increase the number of a part of beneficial bacteria in the intestines of animals, and improve the structure of intestinal flora. In particular, the number of Akkermansia muciniphila in the intestines of animals can be significantly increased, and then the intestinal barrier function is improved through the regulating effect of intestinal flora, so that diseases such as obesity, diabetes, hyperlipidemia and the like are prevented or treated.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Quality evaluation method of cortex phellodendri medicinal material and application of quality evaluation method
The invention relates to a quality evaluation method of a cortex phellodendri medicinal material and application thereof. Based on a multi-component alkaloid-phenolic acid-limonin synergistic effect mechanism of cortex phellodendri, berberine hydrochloride (alkaloid) and 3-O- / 5-O-feruloylquinic acid (phenolic acid) are introduced into a synchronous detection system for the first time; the defect that only two alkaloids, namely berberine hydrochloride and phellodendrine hydrochloride, are monitored in the existing pharmacopoeia, but key active components with remarkable anti-inflammatory and antioxidant activity, such as phenolic acids, are ignored, is overcome. The invention discloses a variable importance projection (VIP) algorithm based on a PLS-DA model. According to the method, 9 components are taken as the screening standard of symbolic components, core characteristic components including berberine hydrochloride and 3-O- / 5-O-feruloylquinic acid which contribute to the quality difference are intelligently screened from the 9 components, and the quality grades of different batches of cortex phellodendri medicinal materials are distinguished, so that the quality difference identification sensitivity is greatly improved; and a precise target spot is provided for producing area traceability and process regulation and control. By adopting the quality evaluation method provided by the invention, not only is the overall chemical substance basis of the medicinal materials comprehensively reflected, but also the quality grades of different batches of cortex phellodendri medicinal materials can be distinguished and the high-quality production area of cortex phellodendri can be locked through the VIP characteristic components.
Owner:FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE
Composition for promoting height growth, comprising berberine chloride hydrate as active ingredient
PCT designated stageWO2026084421A1Organic active ingredientsSkeletal disorderSomatotropic hormoneChild and adolescent
The present invention relates to a composition for promoting height growth, the composition comprising berberine chloride hydrate as an active ingredient. The composition according to the present invention can induce a decrease in KMT1A expression, an increase in the expression of a growth hormone receptor or IGF-1, a decrease in binding between KMT1A and a growth hormone receptor promoter, and the like, and thus has the effect of promoting height growth in children or adolescents during the growth phase, and can have the effect of preventing, alleviating or treating height growth disorders, and thus can be used as a material in foods, pharmaceuticals, feeds, and the like.
Owner:KOREA FOOD RES INST
Drug targeting and sustained release method of posthypospadias repair degradable stent
The application relates to the technical field of biological medicine, and particularly discloses a preparation method of a post-hypospadias surgery degradable stent with drug-targeting slow release. The product composition comprises a stent base body composed of left-handed polylactic acid and polycaprolactone, drug-loaded slow-release microspheres containing polylactic acid-hydroxyacetic acid copolymer, berberine hydrochloride, sirolimus and folic acid, sodium alginate and calcium chloride for fixing the microspheres, and a hyaluronic acid coating layer on the surface of the stent. The preparation method comprises the following steps: first, preparing the stent base body containing multiple levels of pores; second, preparing the drug slow-release microspheres; third, compounding the microspheres with the stent; fourth, performing surface lubricating coating treatment after cross-linking and fixing the microspheres; and fifth, sterilizing and packaging. The product can be used after hypospadias surgery, has the functions of urethral support and drug-targeting slow release, has the advantages that the degradation rate is adapted to the tissue repair period, and the multiple levels of pores are beneficial to cell climbing; and the preparation method has the advantages that the process controllability is high, each step cooperatively guarantees the product performance, and is suitable for medical implant production.
Owner:福建省儿童医院